Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 6, 2011, Pages 1611-1617

  Van Staveren, Maurice C ^a   Theeuwes Oonk, Barbara ^d   Guchelaar, Henk Jan ^b   Van Kuilenburg, André B P ^c   Maring, Jan Gerard ^d  

^a Scheper Ziekenhuis   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Bethesda Hospital   (Netherlands)

Author keywords

5 fluorouracil; Cancer; Dihydropyrimide dehydrogenase; Pharmacokinetics; Uracil

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; FLUOROURACIL; URACIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PLASMA CLEARANCE; PRIORITY JOURNAL; REPEATED DRUG DOSE; REPRODUCIBILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AGED; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; FEMALE; HUMANS; MALE; MIDDLE AGED; URACIL;

EID: 82455209056     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1661-5     Document Type: Article

References (38)

1. HM Pinedo GF Peters 1988 Fluorouracil: biochemistry and pharmacology J Clin Oncol 6 10 1653 1664 3049954 1:CAS:528:DyaL1MXotA%3D%3D
2. RB Diassio BE Harris 1989 Clinical pharmacology of 5-fluorouracil Clin Phamacokinet 16 215 237 10.2165/00003088-198916040-00002 (Pubitemid 19114713)
3. MC Etienne JL Lagrange O Dassonville, et al. 1994 Population study of dihydropyrimidine dehydrogenase in cancer patients with advanced colorectal cancer J Clin Oncol 12 11 2248 2253 7964939 1:STN:280:DyaK2M%2FlsVansQ%3D%3D (Pubitemid 24346691)
4. RA Flemming G Milano, et al. 1992 Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients Cancer Res 52 2899 2902
5. BE Harris R Song 1990 Relation between dihydropyrimidine dehydrogenase and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil bij protracted continuous infusion Cancer Res 50 197 201 2293556 1:STN:280:DyaK3c%2FnsFWnsA%3D%3D (Pubitemid 20030018)
6. JG Maring ABP van Kuilenburg J Haasjes, et al. 2002 Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene Br J Cancer 86 1028 1033 11953843 10.1038/sj.bjc.6600208 1:CAS:528:DC%2BD38XjvFGisrg%3D (Pubitemid 34438069)
7. ABP van Kuilenburg JG Maring A Schalhom, et al. 2008 Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene Nucleosides Nucleotides Nucleic Acids 27 692 698 18600527 10.1080/15257770802145009 (Pubitemid 351948568)
8. J Ciccolini C Mercier L DAhan A Evrard JC Boyer K Richard JP Dales A Durand G Milano JF Seitz B Lacarelle 2006 Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency Cancer Chemother Pharmacol 58 272 275 16292536 10.1007/s00280-005-0139-8 1:CAS:528:DC%2BD28XjvFGitrw%3D
9. C Mercier J Ciccolini 2007 Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit? Trends Pharmacol Sci 28 12 597 598 18001850 10.1016/j.tips.2007.09.009 1:CAS:528:DC%2BD2sXhtlyrtrfJ (Pubitemid 350176603)
10. ABP van Kuilenburg J Haasjes D Richel, et al. 2006 Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-associated toxicity: identification of new mutations in the DPD gene Clin Cancer Res 6 4705 4712
11. ABP van Kuilenburg R Meinsma L Zoetekouw AH van Gennip 2002 Increased risk of grade IV neutropenia after administration of 5-FU due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1G>A mutation Int J Canc 101 253 258 10.1002/ijc.10599 (Pubitemid 34970893)
12. M Boisdron-Celle G Remaud S Traore AL Poirier L Gamelin A Morel E Gamelin 2007 5-Fluorouracil-related toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency Cancer Lett 249 271 282 17064846 10.1016/j.canlet.2006.09.006 1:CAS:528: DC%2BD2sXjsVekur8%3D (Pubitemid 46452935)
13. CG Yang J Ciccolini A Blesius L Dahan D Bagarry-Liegey C Brunet, et al. 2010 DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity Cancer Chemother Pharmacol 67 49 56 20204365 10.1007/s00280-010-1282-4 1:CAS:528:DC%2BC3cXlsFOht7g%3D
14. ABP van Kuilenburg R Meinsma L Zoetekouw, et al. 2002 High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity Pharmacogenetics 12 7 555 558 12360106 10.1097/00008571-200210000-00007 (Pubitemid 35177085)
15. 13C]dihydrouracil Clin Cancer Res 12 549 555 16428499 10.1158/1078-0432.CCR-05-2020 1:CAS:528:DC%2BD28XmtlKhtw%3D%3D (Pubitemid 43166148)
16. 13C-uracil breath test Clin Cancer Res 10 2652 2658 15102667 10.1158/1078-0432.CCR-03-0374 1:CAS:528:DC%2BD2cXjt1Clt7g%3D (Pubitemid 38509138)
17. 13C-uracil as an in vivo probe British J of Clinical Pharmacol 60 6 584 593 10.1111/j.1365-2125.2005. 02472.x 1:CAS:528:DC%2BD2MXhtlCks7rL (Pubitemid 41705377)
18. J Escoriaza A Aldaz E Calvo, et al. 1999 Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokineticstudies J Chromatogr B Biomed Sci Appl 736 12 97 102 10676988 10.1016/S0378-4347(99)00446-6 1:CAS:528:DyaK1MXnsl2lsL8%3D
19. MH Kristensen P Pedersen J Mejer 2010 The value of dihydrouracil/uracil plasma ratios in predicting 5-Fluorouracil-related toxicity in colorectal cancer patients J Int Med Res 38 4 1313 1323 20926004 1:CAS:528:DC%2BC3cXhsVejtrrN
20. G Bocci C Barbara F Vannozzi A Di Paolo A Melosi G Barsanti G Allegrini A Falcone M Del Tacca R Danesi 2006 A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity Clin Pharmacol Ther 80 4 384 395 17015056 10.1016/j.clpt.2006.06.007 1:CAS:528:DC%2BD28XhtVWqurjI (Pubitemid 44479748)
21. G Bocci A Di Paolo C Barbara G Masi L Fornaro, et al. 2010 Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction Br J of Clin Pharmacol 67 1 132 134 10.1111/j.1365-2125.2008.03307.x
22. J Ciccoline C Mercier A Evrard JC Boyer F Duffaud L Dhan K Richard C Blanquicett A Blesius A Durand JF Seitz R Favre B Lacarelle 2006 A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy Ther Drug Monit 28 5 678 685 10.1097/01.ftd.0000245771.82720.c7 (Pubitemid 44564069)
23. B Daoqin LW Anderson J Shapiro A Shapiro JL Grem CH Takimoto 2000 Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase J Chromatorgr B 738 249 258 10.1016/S0378-4347(99)00528-9 (Pubitemid 30089451)
24. RB Fredj E Gross SB Ahmed H Hassine S Saguem 2009 The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis or screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil Pathol Biol 57 6 470 476 18619742 10.1016/j.patbio.2008.05.001
25. J Ciccolini C Mecier MF Blanchon R Favre A Durand B Lacarelle 2004 A simple and rapid high-performance liquid chromatographic (HPLC) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity J Clin Pharm Ther 29 307 315 15271097 10.1111/j.1365-2710.2004. 00569.x 1:CAS:528:DC%2BD2cXntFGltbg%3D (Pubitemid 39062160)
26. ZW Zhou GQ Wang S de Wan ZH Lu YB Chen S Li G Chen ZZ Pan 2007 The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients Chemotherapy 53 2 127 131 17308379 10.1159/000099984 1:CAS:528:DC%2BD2sXisFygs70%3D (Pubitemid 46377220)
27. E Gamelin M Boisdron-Celle V Guérin-Meyer R Delva A Lortholary F Genevieve F Larra N Ifrah J Robert 1999 Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage J Clin Oncol 17 4 1105 1110 10561167 1:CAS:528:DyaK1MXisFentb0%3D (Pubitemid 29162932)
28. ABP van Kuilenburg H van Lenthe A Tromp PCJ Veltman AH van Gennip 2000 Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency Clin Chem 46 9 17 10620566 (Pubitemid 30090954)
29. JG Maring L Schouten B Greijdanus EG de Vries DR Uges 2005 A simple and sensitive fully validated HPLC-UV method for the determination of 5-fluorouracil and its metabolite 5, 6-dihydrofluorouracil in plasma Ther Drug Monit 27 1 25 30 15665742 10.1097/00007691-200502000-00006 1:CAS:528:DC%2BD2MXmtVWmsQ%3D%3D (Pubitemid 40189969)
30. U Klotz 2009 Pharmacokinetics and drug metabolism in the elderly Drug Metab Rev 41 2 67 76 19514965 10.1080/03602530902722679 1:CAS:528: DC%2BD1MXnsVagsrc%3D
31. C Aymanns F Keller S Maus B Hartmann, et al. 2010 Review on pharmacokinetics and pharmacodynamics and the aging kidney Clin J Am Soc Nephrol 5 2 314 327 20056753 10.2215/CJN.03960609 1:CAS:528:DC%2BC3cXjs12ku7c%3D
32. G Ramadori S Cameron 2010 Effects of systemic chemotherapy on the liver Ann Hepatol 9 2 133 143 20526005 1:CAS:528:DC%2BC3cXht1KlsL%2FN
33. JG Maring H Piersma A van Dalen HJ Groen DR Uges EG De Vries 2003 Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics Cancer Chemother Pharmacol 51 2 167 173 12647019 1:CAS:528:DC%2BD3sXit1Sgsr8%3D (Pubitemid 36259478)
34. MJ O'Connell 1989 A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study Cancer 63 1026 1030 2465076 10.1002/1097-0142(19890315)63: 6+<1026::AID-CNCR2820631307>3.0.CO;2-R (Pubitemid 19081268)
35. ML Rothenberg AM Oza RH Bigelow JD Berlin JL Marshall RK Ramanathan, et al. 2003 Superiority of oxaliplatin and fluorouracil and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinoctecan and fluorouracil-leucovorin: interi results of a phase III trial J Clin Oncol 21 1897 1905
36. DJ Stewart WK Evans FA Shepard KS Wilson KI Pritchard MF Trudeau, et al. 1997 Cyclofosfamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin J Clin Oncol 15 1897 1905 9164200 1:CAS:528:DyaK2sXjsVCltbc%3D (Pubitemid 27209519)
37. D Amadori O Nanni M Marangolo R Pacini A Ravaioli A Rossi, et al. 2000 Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomised multicenter study J Clin Oncol 18 3125 3134 10963641 1:CAS:528:DC%2BD3cXntVCgsb0%3D
38. 13C] dihydrouracil Clin Cancer Res 12 2 549 555 16428499 10.1158/1078-0432.CCR-05-2020 1:CAS:528:DC%2BD28XmtlKhtw%3D%3D (Pubitemid 43166148)